WallStSmart

Sabra Healthcare REIT Inc (SBRA)vsVentas Inc (VTR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ventas Inc generates 643% more annual revenue ($6.42B vs $863.77M). SBRA leads profitability with a 7.6% profit margin vs 4.1%. VTR appears more attractively valued with a PEG of 5.15. SBRA earns a higher WallStSmart Score of 43/100 (D).

SBRA

Hold

43

out of 100

Grade: D

Growth: 5.3Profit: 3.5Value: 4.7Quality: 5.5
Piotroski: 3/9Altman Z: 0.39

VTR

Hold

41

out of 100

Grade: D

Growth: 6.0Profit: 4.5Value: 2.0Quality: 4.0
Piotroski: 4/9Altman Z: 0.43
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SBRAUndervalued (+84.4%)

Margin of Safety

+84.4%

Fair Value

$125.35

Current Price

$20.52

$104.83 discount

UndervaluedFair: $125.35Overvalued
VTRSignificantly Overvalued (-16.5%)

Margin of Safety

-16.5%

Fair Value

$76.72

Current Price

$89.99

$13.27 premium

UndervaluedFair: $76.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SBRA2 strengths · Avg: 8.0/10
Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
25.3%8/10

Revenue surging 25.3% year-over-year

VTR1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
21.7%8/10

Revenue surging 21.7% year-over-year

Areas to Watch

SBRA4 concerns · Avg: 2.8/10
Return on EquityProfitability
5.6%3/10

ROE of 5.6% — below average capital efficiency

Profit MarginProfitability
7.6%3/10

7.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

VTR4 concerns · Avg: 2.5/10
Return on EquityProfitability
1.8%3/10

ROE of 1.8% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

PEG RatioValuation
5.152/10

Expensive relative to growth rate

P/E RatioValuation
163.4x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : SBRA

The strongest argument for SBRA centers on Price/Book, Revenue Growth. Revenue growth of 25.3% demonstrates continued momentum.

Bull Case : VTR

The strongest argument for VTR centers on Revenue Growth. Revenue growth of 21.7% demonstrates continued momentum.

Bear Case : SBRA

The primary concerns for SBRA are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 80.0x leaves little room for execution misses.

Bear Case : VTR

The primary concerns for VTR are Return on Equity, Profit Margin, PEG Ratio. A P/E of 163.4x leaves little room for execution misses. Thin 4.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

VTR carries more volatility with a beta of 0.72 — expect wider price swings.

SBRA is growing revenue faster at 25.3% — sustainability is the question.

SBRA generates stronger free cash flow (61M), providing more financial flexibility.

Monitor REIT - HEALTHCARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SBRA scores higher overall (43/100 vs 41/100) and 25.3% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sabra Healthcare REIT Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

As of September 30, 2020, Sabra's investment portfolio included 425 real estate properties held for investment (consisting of (i) 287 skilled nursing / transitional care facilities, (ii) 64 senior housing communities (?

Ventas Inc

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Ventas, Inc. is a real estate investment trust specializing in the ownership and management of health care facilities in the United States, Canada and the United Kingdom.

Want to dig deeper into these stocks?